Under a tenth of patients eligible to benefit from obesity jabs including Wegovy can access them, warns the global health agency as it issues its initial guidance on the drugs.
Considering in excess of 1,000,000,000 people worldwide now living with obesity, it is calling for increased and just availability to these injectable treatments.
According to estimates, in excess of 2,000,000,000 could be living with obesity by 2030 unless action is taken.
"The new guidance affirms that obesity is a long-term condition that can be treated with thorough and lifelong treatment," said its chief Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and supply-chain constraints are significant hurdles to universal access to the injections that can assist patients in reducing substantial weight, notes the organization.
Skinny Jab Supply Crisis
Despite the present most favorable case, the manufacturing of GLP-1 therapies might only reach around 100 million people – under 10% of eligible patients, according to the WHO.
The advice encourages nations and manufacturers to increase access, by approaches including patent sharing.
The intellectual property rights on a key compound – the core component of the drug Wegovy – is set to lapse in a number of countries in 2026.
How Weight-Loss Drugs Operate
GLP-1 drugs replicate a natural hormone to delay gastric emptying, reduce hunger and boost satiety so users eat less.
Patients usually begin shedding pounds in the initial weeks of commencing the weekly injections.
Studies points to users may regain a significant portion within a year of stopping the medication, because their typical food cravings return.
To be above a healthy weight elevates your likelihood for experiencing health problems, like type 2 diabetes, cardiovascular issues, brain attack, and specific malignancies.
Obesity affects people in countries worldwide and was linked to millions of deaths worldwide in 2024, according to the WHO.
